605 Results
Sort By:
Published on April 7, 2023
University of Pittsburgh researchers have detailed how probiotic bacteria travel from the gut to cancer tumors and then stimulate immune cells to make melanoma immunotherapy more effective. The team showed that Lactobacillu reuteri, a lactic acid bacterium and known probiotic, stimulates cancer-killing T cells to secrete the compound idole-3-aldehyde (I3A).…
Published on April 4, 2023
Originally Aired: April 6, 2023Time: 11:00 am PT, 2:00 pm ET, 20:00 CET VIEW NOW Immune checkpoint inhibition with monoclonal antibodies targeting PD-1 and PD-L1 has revolutionized the care of patients with advanced cancer, with approvals in multiple solid tumor types and pan-tumor indications. However, current pan-tumor biomarkers do not identify most patients…
Published on March 1, 2023
New research shows that using a chemical blocker stops CD8+ T cells from migrating out of skin cancer cells. Together with immunotherapy, the combination stopped melanoma tumor growth in half of treated mice, representing a potential new approach for boosting the efficacy of immunotherapy. In a paper in Nature Immunology,…
Published on February 22, 2023
CD5+ cells could be an important marker for response to immunotherapy, according to new research from the Washington University School of Medicine. In lab studies, this team found that patients whose tumor samples had more CD5+ dendritic cells lived longer. Also, mice without CD5 on their dendritic cells did not…
Published on February 8, 2023
Researchers at the Massachusetts Institute of Technology (MIT) has found in a mouse study that bacteria naturally found in the lungs help create an environment that suppresses T-cell activation in the lymph nodes near the lungs—a finding that could explain why immunotherapy for lung cancer often fails. The same immune-supressive environment…
Published on January 26, 2023
Tumor mutation burden (TMB) has become a biomarker used to predict patient response to specific immunotherapies. Now, new evidence from researchers at the Johns Hopkins Kimmel Cancer Center have found that a subset of mutations within the TMB—defined at “persistent mutations”—are less likely than others to be edited out, making…
Published on January 25, 2023
A team of researchers from Moffitt Cancer Center have shown a novel approach to increase the numbers of tumor-infiltrating lymphocytes (TILs) and their antitumor activity. In research published in Nature Cancer, the investigators demonstrate, in mouse models, how L-fucose, a nontoxic dietary plant sugar that is enriched in red and brown…
Published on January 11, 2023
Researchers in China have shown that using immune checkpoint inhibitors prior to surgery of patients with localized mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC) is an effective approach to treating the disease, as opposed to surgery followed by neoadjuvant therapy. The findings, published in JNCCN—Journal of the National…
Published on December 28, 2022
Gilead Sciences and Jounce Therapeutics announced late Tuesday amendments to the existing terms and licensing agreements for GS-1811 (previously called JTX-1811), a potential first-in-class anti-CCR8 antibody in development as a potential treatment against solid tumors. The new deal will see the termination of certain operational obligations and Gilead will buy…
Published on December 21, 2022
Scientists at the University of Pittsburgh have discovered that tired T cells not only lose their own ability to fight cancer; they also influence surrounding cells to suppress an immune response. And they learned that one of the drivers of exhausted T cells is an environment low in oxygen. In…
Published on December 14, 2022
Clinical-stage biopharma Qu Biologics has announced a collaboration with Sweden’s Karolinska Institute (KI) to characterize the molecular targets of Qu’s Site Specific Immunomodulators (SSIs), an immunotherapy platform designed to restore innate immune function. The research will be led by Prof. Jonas Fuxe, who will become the head of laboratory medicine…
Published on December 13, 2022
Adding the immunotherapy blinatumomab after an initial round of consolidation chemotherapy in patients with good prognosis with B lineage acute lymphoblastic leukemia (ALL) kept most patients in remission and improved survival. Results of the randomized Phase III study showed that after three-and-a-half years of follow up, 83% of patients who…
Published on December 12, 2022
A genetic marker can identify patients at high risk of potentially serious side effects from immunotherapy used to treat melanoma skin cancer. Researchers identified the first genetic risk factor for immunotherapy toxicity in the IL-7 gene, which codes for an important factor in lymphocyte survival. Carriers had up to a…
Published on December 7, 2022
In a reversal to accepted theories, scientists have discovered the adding radiation to immunotherapy does not boost the immune system. It’s actually the reverse. Yet, in several cancers, the combination together shows improved treatment responses over either treatment alone. The reason may have more to do with the tumor’s aneuploidy…
Published on December 7, 2022
Cancer patients’ response to immunotherapy may be predictable in part based on their levels of CD8+ T-cell infiltration, according to a new study. Such drugs are one of the world’s highest selling classes, estimated to have netted over $31B in 2021 and expected to bring almost $150M by 2030. But…